vs
Beam Therapeutics Inc.（BEAM）与GRID DYNAMICS HOLDINGS, INC.（GDYN）财务数据对比。点击上方公司名可切换其他公司
Beam Therapeutics Inc.的季度营收约是GRID DYNAMICS HOLDINGS, INC.的1.1倍（$114.1M vs $104.1M），Beam Therapeutics Inc.净利率更高（214.1% vs -1.4%，领先215.5%），Beam Therapeutics Inc.同比增速更快（279.5% vs 3.7%）
Beam Therapeutics是一家美国生物技术企业，专注于基因治疗与基因组编辑领域的研发，总部位于马萨诸塞州剑桥市。公司依托CRISPR碱基编辑和先导编辑技术，可通过酶促作用修改DNA序列中的单个核苷酸，且不会造成DNA双链断裂，以此开发相关治疗方案。
Escape Dynamics Inc.是一家总部位于科罗拉多州的科技企业，活跃于2010年至2015年，核心业务方向是研发可单级入轨、依靠电磁驱动的可重复使用航天飞机，并推动该项目实现商业化落地。
BEAM vs GDYN — 直观对比
营收规模更大
BEAM
是对方的1.1倍
$104.1M
营收增速更快
BEAM
高出275.8%
3.7%
净利率更高
BEAM
高出215.5%
-1.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $114.1M | $104.1M |
| 净利润 | $244.3M | $-1.5M |
| 毛利率 | — | 34.8% |
| 营业利润率 | -15.3% | 61.7% |
| 净利率 | 214.1% | -1.4% |
| 营收同比 | 279.5% | 3.7% |
| 净利润同比 | 370.4% | -150.6% |
| 每股收益（稀释后） | $2.53 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BEAMGDYN
| Q1 26 | — | $104.1M | ||
| Q4 25 | $114.1M | $106.2M | ||
| Q3 25 | — | $104.2M | ||
| Q2 25 | — | $101.1M | ||
| Q1 25 | — | $100.4M | ||
| Q4 24 | — | $100.3M | ||
| Q3 24 | — | $87.4M | ||
| Q2 24 | — | $83.0M |
净利润BEAMGDYN
| Q1 26 | — | $-1.5M | ||
| Q4 25 | $244.3M | $306.0K | ||
| Q3 25 | — | $1.2M | ||
| Q2 25 | — | $5.3M | ||
| Q1 25 | — | $2.9M | ||
| Q4 24 | — | $4.5M | ||
| Q3 24 | — | $4.3M | ||
| Q2 24 | — | $-817.0K |
毛利率BEAMGDYN
| Q1 26 | — | 34.8% | ||
| Q4 25 | — | 34.0% | ||
| Q3 25 | — | 33.3% | ||
| Q2 25 | — | 34.1% | ||
| Q1 25 | — | 36.8% | ||
| Q4 24 | — | 36.9% | ||
| Q3 24 | — | 37.4% | ||
| Q2 24 | — | 35.6% |
营业利润率BEAMGDYN
| Q1 26 | — | 61.7% | ||
| Q4 25 | -15.3% | 0.5% | ||
| Q3 25 | — | -0.2% | ||
| Q2 25 | — | -0.1% | ||
| Q1 25 | — | -2.0% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 2.4% | ||
| Q2 24 | — | 0.0% |
净利率BEAMGDYN
| Q1 26 | — | -1.4% | ||
| Q4 25 | 214.1% | 0.3% | ||
| Q3 25 | — | 1.1% | ||
| Q2 25 | — | 5.2% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | — | 4.5% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | -1.0% |
每股收益（稀释后）BEAMGDYN
| Q1 26 | — | $-0.02 | ||
| Q4 25 | $2.53 | $0.01 | ||
| Q3 25 | — | $0.01 | ||
| Q2 25 | — | $0.06 | ||
| Q1 25 | — | $0.03 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | — | $0.05 | ||
| Q2 24 | — | $-0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $327.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $530.1M |
| 总资产 | $1.5B | $605.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BEAMGDYN
| Q1 26 | — | $327.5M | ||
| Q4 25 | $1.2B | $342.1M | ||
| Q3 25 | — | $338.6M | ||
| Q2 25 | — | $336.8M | ||
| Q1 25 | — | $325.5M | ||
| Q4 24 | — | $334.7M | ||
| Q3 24 | — | $231.3M | ||
| Q2 24 | — | $256.0M |
股东权益BEAMGDYN
| Q1 26 | — | $530.1M | ||
| Q4 25 | $1.2B | $542.1M | ||
| Q3 25 | — | $537.7M | ||
| Q2 25 | — | $532.2M | ||
| Q1 25 | — | $517.4M | ||
| Q4 24 | — | $517.8M | ||
| Q3 24 | — | $400.2M | ||
| Q2 24 | — | $388.4M |
总资产BEAMGDYN
| Q1 26 | — | $605.0M | ||
| Q4 25 | $1.5B | $612.9M | ||
| Q3 25 | — | $613.2M | ||
| Q2 25 | — | $608.9M | ||
| Q1 25 | — | $590.9M | ||
| Q4 24 | — | $592.2M | ||
| Q3 24 | — | $477.3M | ||
| Q2 24 | — | $443.6M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-83.3M | — |
| 自由现金流经营现金流 - 资本支出 | $-87.0M | — |
| 自由现金流率自由现金流/营收 | -76.3% | — |
| 资本支出强度资本支出/营收 | 3.3% | — |
| 现金转化率经营现金流/净利润 | -0.34× | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流BEAMGDYN
| Q1 26 | — | — | ||
| Q4 25 | $-83.3M | $9.9M | ||
| Q3 25 | — | $7.0M | ||
| Q2 25 | — | $14.4M | ||
| Q1 25 | — | $9.4M | ||
| Q4 24 | — | $7.1M | ||
| Q3 24 | — | $9.2M | ||
| Q2 24 | — | $10.7M |
自由现金流BEAMGDYN
| Q1 26 | — | — | ||
| Q4 25 | $-87.0M | $6.1M | ||
| Q3 25 | — | $2.9M | ||
| Q2 25 | — | $10.2M | ||
| Q1 25 | — | $6.0M | ||
| Q4 24 | — | $4.4M | ||
| Q3 24 | — | $5.9M | ||
| Q2 24 | — | $8.0M |
自由现金流率BEAMGDYN
| Q1 26 | — | — | ||
| Q4 25 | -76.3% | 5.7% | ||
| Q3 25 | — | 2.8% | ||
| Q2 25 | — | 10.1% | ||
| Q1 25 | — | 6.0% | ||
| Q4 24 | — | 4.4% | ||
| Q3 24 | — | 6.8% | ||
| Q2 24 | — | 9.7% |
资本支出强度BEAMGDYN
| Q1 26 | — | — | ||
| Q4 25 | 3.3% | 3.6% | ||
| Q3 25 | — | 3.9% | ||
| Q2 25 | — | 4.1% | ||
| Q1 25 | — | 3.3% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | — | 3.7% | ||
| Q2 24 | — | 3.2% |
现金转化率BEAMGDYN
| Q1 26 | — | — | ||
| Q4 25 | -0.34× | 32.34× | ||
| Q3 25 | — | 5.92× | ||
| Q2 25 | — | 2.73× | ||
| Q1 25 | — | 3.21× | ||
| Q4 24 | — | 1.56× | ||
| Q3 24 | — | 2.15× | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BEAM
| Pfizer | $109.1M | 96% |
| Other | $5.0M | 4% |
GDYN
暂无分部数据
